首页> 美国卫生研究院文献>Oncology Letters >Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report
【2h】

Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report

机译:严重再生障碍性贫血的外周血干细胞移植后供体细胞白血病的发展:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Donor cell leukemia (DCL) is a rare complication of hematopoietic stem cell transplantation (HSCT) which occurs in ~5% of all leukemic relapses. In the English literature, >60 cases of DCL have been reported, however, only two cases of DCL following HSCT for the treatment of severe aplastic anemia (SAA) have been described to date. In the present study, the case of a 25 year-old male patient diagnosed with SAA, who underwent a peripheral blood stem cell transplantation (PBSCT) using cells obtained from a sibling with an identical human leukocyte antigen, is presented. The patient developed acute myeloid leukemia with an (8;21)(q22;q22) translocation and an extra copy of the chromosome 8 in donor cells 2.5 years following PBSCT, which was preceded by the development of Graves' disease 1 year following PBSCT. The leukemia achieved complete remission following 1 cycle of priming therapy, 2 cycles of consolidation chemotherapy with daunorubicin and cytarabine and maintenance therapy with interleukin-2 (IL-2). At present, the patient has discontinued IL-2 therapy, and the DCL has been in molecular remission for >3 years. The present case indicates that chemotherapy and IL-2 maintenance therapy are an effective treatment for DCL; hyperthyroidism was relieved following treatment, although hypothyroidism subsequently developed.
机译:供体细胞白血病(DCL)是造血干细胞移植(HSCT)的罕见并发症,约占所有白血病复发的5%。在英语文献中,已报道了60例DCL,但是迄今为止,仅描述了HSCT后用于治疗严重再生障碍性贫血(SAA)的DCL 2例。在本研究中,介绍了一名25岁的诊断为SAA的男性患者,该患者使用从同胞中获得的具有相同人类白细胞抗原的细胞进行了外周血干细胞移植(PBSCT)。患者在PBSCT发生2.5年后在供体细胞中发生了(8; 21)(q22; q22)易位和8号染色体的额外复制的急性髓细胞白血病,随后在PBSCT发生1年后出现了Graves病。在1个周期的启动治疗,2个周期的柔红霉素和阿糖胞苷巩固化疗以及白介素2(IL-2)维持治疗后,白血病实现了完全缓解。目前,该患者已停止IL-2治疗,DCL的分子缓解期已超过3年。目前的情况表明化疗和IL-2维持疗法是DCL的有效治疗方法。治疗后甲状腺功能亢进得到缓解,尽管随后甲状腺功能减退得以发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号